Most Read

Maxigesic IV, which is a combination of 1000mg paracetamol and 300mg ibuprofen solution, is given intravenously to adults for relieving mild to severe pain. It received approval for

The NDA has been submitted based data from the randomised Phase III MARCH PFIC study of LIVMARLI. A total of 93 patients with various generic PFIC subtypes including

Following this approval, Knight expects to launch Minjuvi in Brazil in Q2 2024. In July this year, Agência Nacional de Vigilância Sanitária (ANVISA) granted market authorisation under the

CHMP also recommended approval of the anti-programmed death receptor-1 (PD-1) therapy. It recommended approval of KEYTRUDA along with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for locally advanced

With this expansion and added production line, the company can now offer more plasmid material in quality and GMP grades as well as extend the mRNA supply services.

The multicentre, open-label study will evaluate the autologous fully human anti-cd19 chimeric antigen receptor (CAR) T cell therapy KYV-101 in adult scleroderma patients. Kyverna Therapeutics CEO Peter Maag

The contract was signed through TaiGen’s subsidiary company TaiGen Biotechnology. Considering the competitiveness of the pharmaceutical market as well as concerns about proprietary information, the companies did not

CST-3056 is an alpha-1A adrenoceptor (α1A-AR) agonist, and is still in preclinical development. Alzheimer’s Drug Discovery Foundation co-founder and chief science officer Howard Fillit said: “Alpha-1A adrenoceptors are

LIVMARLI is claimed to be the first and only approved therapy in Taiwan used for treating cholestatic pruritus in patients with ALGS aged one year or older. Recently,